Antihypertensives Linked to Eczematous Dermatitis in Seniors
By Elana Gotkine HealthDay Reporter
FRIDAY, May 24, 2024 -- Antihypertensive drugs are associated with an increased risk for eczematous dermatitis in older adults, and the effect sizes are largest for diuretics and calcium channel blockers, according to a study published online May 22 in JAMA Dermatology.
Morgan Ye, M.P.H., from the University of California in San Francisco, and colleagues examined whether antihypertensive drug use is associated with eczematous dermatitis in a longitudinal cohort study of individuals aged 60 years and older without eczematous dermatitis at baseline.
The researchers found that the overall prevalence of eczematous dermatitis was 6.7 percent among 1,561,358 older adults during a median follow-up of six years. The incidence of eczematous dermatitis was higher among those receiving versus those not receiving antihypertensive drugs (12 versus 9 of 1,000 person-years of follow-up). Participants who received any antihypertensive drugs had a significantly increased risk for any eczematous dermatitis in adjusted analyses (hazard ratio, 1.29). When assessing each antihypertensive drug class individually, the largest effect sizes were seen for diuretics and calcium channel blockers, while the effect sizes were smallest for angiotensin-converting enzyme inhibitors and β-blockers (hazard ratios, 1.21, 1.16, 1.02, and 1.04, respectively).
"Although additional research is needed to understand the mechanisms underlying the association of antihypertensive drug use and eczematous dermatitis, these data could be helpful to clinicians to guide clinical management when an older patient presents with eczematous dermatitis," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
Hypertensive Disorders of Pregnancy Adversely Affect Preemie Neurodevelopment
THURSDAY, May 1, 2025 -- Maternal hypertensive disorders of pregnancy (HDP) are associated with adverse cognitive and language development in preterm infants at 2 years' corrected...
Lorundrostat Beneficial for BP Reduction in Uncontrolled Hypertension
WEDNESDAY, April 30, 2025 -- For patients with uncontrolled and treatment-resistant hypertension, lorundrostat is associated with greater reductions in blood pressure than...
Intensive BP Reduction Effective for Lowering All-Cause Dementia Risk
TUESDAY, April 29, 2025 -- An intensive blood pressure (BP) reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.